We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Insights Into QuidelOrtho (QDEL) Q4: Wall Street Projections for Key Metrics
Read MoreHide Full Article
The upcoming report from QuidelOrtho (QDEL - Free Report) is expected to reveal quarterly earnings of $2.02 per share, indicating an increase of 14.8% compared to the year-ago period. Analysts forecast revenues of $798.24 million, representing a decrease of 7.9% year over year.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
With that in mind, let's delve into the average projections of some QuidelOrtho metrics that are commonly tracked and projected by analysts on Wall Street.
It is projected by analysts that the 'Net Revenues by product- Molecular Diagnostic Solutions' will reach $10.05 million. The estimate indicates a year-over-year change of -31.2%.
Analysts forecast 'Net Revenues by product- Point-of-Care' to reach $273.47 million. The estimate indicates a change of -27% from the prior-year quarter.
Analysts' assessment points toward 'Net Revenues by product- Transfusion Medicine' reaching $161.76 million. The estimate indicates a year-over-year change of -0.5%.
According to the collective judgment of analysts, 'Net Revenues by product- Labs' should come in at $344.71 million. The estimate indicates a year-over-year change of +9.5%.
Over the past month, shares of QuidelOrtho have returned -6.6% versus the Zacks S&P 500 composite's +5.8% change. Currently, QDEL carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Insights Into QuidelOrtho (QDEL) Q4: Wall Street Projections for Key Metrics
The upcoming report from QuidelOrtho (QDEL - Free Report) is expected to reveal quarterly earnings of $2.02 per share, indicating an increase of 14.8% compared to the year-ago period. Analysts forecast revenues of $798.24 million, representing a decrease of 7.9% year over year.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
With that in mind, let's delve into the average projections of some QuidelOrtho metrics that are commonly tracked and projected by analysts on Wall Street.
It is projected by analysts that the 'Net Revenues by product- Molecular Diagnostic Solutions' will reach $10.05 million. The estimate indicates a year-over-year change of -31.2%.
Analysts forecast 'Net Revenues by product- Point-of-Care' to reach $273.47 million. The estimate indicates a change of -27% from the prior-year quarter.
Analysts' assessment points toward 'Net Revenues by product- Transfusion Medicine' reaching $161.76 million. The estimate indicates a year-over-year change of -0.5%.
According to the collective judgment of analysts, 'Net Revenues by product- Labs' should come in at $344.71 million. The estimate indicates a year-over-year change of +9.5%.
View all Key Company Metrics for QuidelOrtho here>>>
Over the past month, shares of QuidelOrtho have returned -6.6% versus the Zacks S&P 500 composite's +5.8% change. Currently, QDEL carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>